Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.70 |
| ▸ | LCK | P06239 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.70 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036283 | 0.89 | KDM4E (0.67) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL6382667 | 0.86 | KDM6B (0.70) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL17382574 | 0.84 | MDM2 (0.59) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL18469325 | 0.84 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29350434 | 0.84 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29869020 | 0.84 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL5691448 | 0.84 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL829784 | 0.84 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| Levodopa SCHEMBL116907 | 0.82 | SLC7A5 (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL6535013 | 0.82 | KDM6B (0.96) | KDM6BKDM4EHSD17B10TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | KDM6B 3013/4885KDM4E 3685/4885HSD17B10 364/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | KDM6B 54/4885KDM4E 359/4885HSD17B10 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.